San Diego, CA -- (SBWIRE) -- 07/13/2016 -- Juno Therapeutics is under investigation over potential securities laws violations. The investigation was announced on behalf of investors of NASDAQ:JUNO shares in connection certain financial statements made by Juno Therapeutics.

Investors who purchased shares of Juno Therapeutics Inc (NASDAQ:JUNO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Juno Therapeutics Inc (NASDAQ:JUNO) concerning whether certain statements by Juno Therapeutics Inc (NASDAQ:JUNO regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 7, 2016, Juno Therapeutics Inc announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), known as the "ROCKET" trial. Juno Therapeutics Inc said that the clinical hold was initiated after two patient deaths one week earlier, which followed the recent addition of fludarabine to the pre-conditioning regimen.

Shares of Juno Therapeutics Inc (NASDAQ:JUNO) declined on July 12, 2016 to as low as $27.15 per share.

Those who purchased shares of Juno Therapeutics Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com